Loading provider…
Loading provider…
Pulmonary Disease Physician in Los Angeles, CA
NPI: 1063617116Primary Practice Location
RONALD REAGAN UCLA MEDICAL CENTER
757 Westwood Plz, Los Angeles, CA
Primary Employer
UCLA Medical Plaza
uclahealth.org
HQ Phone
Get MD Stephen's Phone Numberphone_androidMobile
Get MD Stephen's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
2003 - 2027
CA State Medical License

American Board of Internal Medicine
Critical Care Medicine

American Board of Internal Medicine
Pulmonary Disease
Creighton University School of Medicine - Omaha
creighton.edu
Medical School
Until 2001
UCLA David Geffen School of Medicine/UCLA Medical Center
Fellowship • Pulmonary Disease and Critical Care Medicine
2004 - 2007
Residency • Internal Medicine
2002 - 2004
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 58 | 146 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 41 | 58 |
| 3 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 39 | 146 |
| 4 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 31 | 83 |
| 5 | 99213Established patient office or other outpatient visit, typically 15 minutes | 21 | 26 |
Molecular diagnostics for lung transplant rejection: An information pipeline or a pipe dream?
Authors: Weigt, S Samuel, Shino, Michael Y, Wang, Xiaoyan
Journal: J Heart Lung Transplant
Time Course and Degree of Hyperinflation with Metronome-Paced Tachypnea in COPD Patients
Authors: Donald Tashkin, Christopher Cooper
Journal: COPD
Inflammasomes and IL-1 biology in the pathogenesis of allograft dysfunction.
Authors: S Weigt, Vyacheslav Palchevskiy, John Belperio
Publication Date: 2017-06-02
Lead Sponsor: Zambon SpA
Intervention / Treatment: DRUG: standard of care, DRUG: Liposomal Cyclosporine A
Lead Sponsor: Zambon SpA
Intervention / Treatment: DRUG: Standard of Care, DRUG: Liposomal Cyclosporine A
Lead Sponsor: Michael Roth
Collaborators: Genentech, Inc., University of California, Los Angeles, University of Michigan
Intervention / Treatment: DRUG: Mycophenolate Mofetil (MMF), DRUG: Pirfenidone (PFD), DRUG: Placebo (Plac)